Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02514252 · ClinicalTrials.gov registry record · Phase 2
Sublingual Fentanyl for the Management of Breakthrough Pain
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02514252: Clinical Trial Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT02514252 is a Phase 2 study that was terminated before completion, run by M.D. Anderson Cancer Center. The registered enrollment target is 6 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02514252, a Phase 2 study, was terminated before completion, sponsored by M.D. Anderson Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if an investigational dose of fentanyl sublingual spray (FSS) can help to control pain in patients with advanced cancer when given in an outpatient and inpatient setting.
Interventions
- BEHAVIORAL Questionnaires
- BEHAVIORAL Mental Ability Tests
- DRUG Fentanyl Sublingual Spray (FSS)
- BEHAVIORAL Study Diary
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2016-02-02 |
| Est. Completion | 2019-11-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02514252
The ClinicalTrials.gov registry entry for NCT02514252 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Questionnaires is the first listed.
NCT02514252 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02514252 about?
NCT02514252 is a clinical study titled "Sublingual Fentanyl for the Management of Breakthrough Pain". The goal of this clinical research study is to learn if an investigational dose of fentanyl sublingual spray (FSS) can help to control pain in patients with advanced cancer when given in an outpatient and inpatient setting.
What is the current status of trial NCT02514252?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2016-02-02. Estimated completion is 2019-11-04.
What interventions are being tested in trial NCT02514252?
The interventions under investigation include: Questionnaires (BEHAVIORAL), Mental Ability Tests (BEHAVIORAL), Fentanyl Sublingual Spray (FSS) (DRUG), Study Diary (BEHAVIORAL).
Who is sponsoring clinical trial NCT02514252?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.